Concepts (212)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Colorectal Neoplasms | 16 | 2021 | 560 | 3.630 |
Why?
|
| Colonic Polyps | 9 | 2015 | 63 | 2.090 |
Why?
|
| Adenoma | 10 | 2021 | 132 | 1.820 |
Why?
|
| Skin Neoplasms | 3 | 2022 | 375 | 1.330 |
Why?
|
| Melanoma | 2 | 2022 | 335 | 1.240 |
Why?
|
| Health Status Disparities | 5 | 2016 | 326 | 1.110 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 3 | 2021 | 91 | 0.870 |
Why?
|
| Immunity | 2 | 2021 | 67 | 0.840 |
Why?
|
| Prognosis | 11 | 2021 | 2093 | 0.810 |
Why?
|
| Hemoglobins | 1 | 2020 | 120 | 0.720 |
Why?
|
| Blood Platelets | 1 | 2020 | 284 | 0.680 |
Why?
|
| Ovarian Neoplasms | 5 | 2019 | 267 | 0.660 |
Why?
|
| Middle Aged | 35 | 2021 | 21119 | 0.660 |
Why?
|
| Colon | 3 | 2021 | 168 | 0.630 |
Why?
|
| Colonic Neoplasms | 2 | 2021 | 299 | 0.610 |
Why?
|
| Aged | 25 | 2022 | 14842 | 0.590 |
Why?
|
| Selenium | 2 | 2009 | 36 | 0.560 |
Why?
|
| Adenomatous Polyps | 1 | 2015 | 18 | 0.540 |
Why?
|
| Medically Uninsured | 1 | 2015 | 99 | 0.510 |
Why?
|
| Female | 34 | 2021 | 38015 | 0.490 |
Why?
|
| Poverty | 1 | 2015 | 218 | 0.490 |
Why?
|
| Humans | 44 | 2022 | 68525 | 0.480 |
Why?
|
| Neoplasm Recurrence, Local | 4 | 2008 | 444 | 0.470 |
Why?
|
| Adenocarcinoma | 1 | 2016 | 475 | 0.470 |
Why?
|
| Male | 31 | 2021 | 37281 | 0.450 |
Why?
|
| DNA Methylation | 2 | 2010 | 192 | 0.420 |
Why?
|
| Patient-Centered Care | 1 | 2013 | 106 | 0.410 |
Why?
|
| Folic Acid | 3 | 2010 | 121 | 0.410 |
Why?
|
| CpG Islands | 2 | 2010 | 51 | 0.410 |
Why?
|
| Tumor Microenvironment | 3 | 2021 | 211 | 0.400 |
Why?
|
| Risk Factors | 13 | 2020 | 5719 | 0.390 |
Why?
|
| Rectum | 1 | 2010 | 62 | 0.380 |
Why?
|
| Body Mass Index | 3 | 2016 | 866 | 0.380 |
Why?
|
| Biomarkers, Tumor | 3 | 2021 | 508 | 0.360 |
Why?
|
| Rectal Diseases | 1 | 2009 | 13 | 0.350 |
Why?
|
| Age Factors | 6 | 2021 | 1860 | 0.350 |
Why?
|
| Adaptation, Psychological | 1 | 2013 | 447 | 0.350 |
Why?
|
| Survival Rate | 4 | 2020 | 1055 | 0.340 |
Why?
|
| Medicare | 2 | 2022 | 316 | 0.340 |
Why?
|
| Dietary Supplements | 5 | 2009 | 331 | 0.340 |
Why?
|
| Diet | 2 | 2009 | 513 | 0.340 |
Why?
|
| Colonoscopy | 6 | 2015 | 156 | 0.330 |
Why?
|
| Proportional Hazards Models | 5 | 2020 | 791 | 0.330 |
Why?
|
| Life Style | 2 | 2009 | 338 | 0.320 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2009 | 138 | 0.310 |
Why?
|
| Computational Biology | 2 | 2019 | 190 | 0.310 |
Why?
|
| Smoking | 6 | 2022 | 1449 | 0.280 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2016 | 536 | 0.270 |
Why?
|
| Calcium Compounds | 1 | 2004 | 3 | 0.250 |
Why?
|
| Physical Fitness | 1 | 2005 | 117 | 0.250 |
Why?
|
| Adenomatous Polyposis Coli | 1 | 2004 | 26 | 0.250 |
Why?
|
| Retrospective Studies | 5 | 2022 | 7264 | 0.250 |
Why?
|
| Models, Statistical | 2 | 2019 | 446 | 0.240 |
Why?
|
| Healthcare Disparities | 2 | 2018 | 378 | 0.230 |
Why?
|
| Smoking Cessation | 2 | 2022 | 1032 | 0.230 |
Why?
|
| Sex Factors | 5 | 2021 | 1265 | 0.230 |
Why?
|
| Aged, 80 and over | 5 | 2016 | 4843 | 0.220 |
Why?
|
| Neoplasm Staging | 3 | 2021 | 799 | 0.220 |
Why?
|
| United States | 5 | 2022 | 7335 | 0.220 |
Why?
|
| Adult | 14 | 2019 | 21375 | 0.220 |
Why?
|
| Cystadenocarcinoma, Serous | 2 | 2019 | 14 | 0.220 |
Why?
|
| Receptors, Nicotinic | 1 | 2022 | 41 | 0.220 |
Why?
|
| CTLA-4 Antigen | 1 | 2022 | 45 | 0.210 |
Why?
|
| Survival Analysis | 2 | 2015 | 714 | 0.210 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2022 | 86 | 0.200 |
Why?
|
| Follow-Up Studies | 7 | 2020 | 3256 | 0.200 |
Why?
|
| Semantics | 1 | 2021 | 37 | 0.200 |
Why?
|
| Neoplasm Invasiveness | 1 | 2021 | 369 | 0.180 |
Why?
|
| Cell Nucleus | 1 | 2021 | 305 | 0.180 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2015 | 624 | 0.180 |
Why?
|
| Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2019 | 10 | 0.170 |
Why?
|
| Tobacco Products | 1 | 2022 | 234 | 0.170 |
Why?
|
| SEER Program | 2 | 2016 | 150 | 0.170 |
Why?
|
| Head and Neck Neoplasms | 2 | 2015 | 561 | 0.170 |
Why?
|
| B7-H1 Antigen | 1 | 2019 | 30 | 0.170 |
Why?
|
| South Carolina | 3 | 2015 | 2750 | 0.170 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2009 | 929 | 0.160 |
Why?
|
| Microbiota | 1 | 2019 | 79 | 0.160 |
Why?
|
| Case-Control Studies | 4 | 2017 | 1548 | 0.160 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2019 | 121 | 0.150 |
Why?
|
| Odds Ratio | 6 | 2017 | 880 | 0.150 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2021 | 689 | 0.150 |
Why?
|
| Linear Models | 4 | 2021 | 521 | 0.140 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2016 | 22 | 0.140 |
Why?
|
| Anticarcinogenic Agents | 2 | 2007 | 52 | 0.140 |
Why?
|
| Tertiary Care Centers | 1 | 2015 | 67 | 0.140 |
Why?
|
| Calcium Carbonate | 2 | 2005 | 7 | 0.130 |
Why?
|
| Spatio-Temporal Analysis | 1 | 2015 | 28 | 0.130 |
Why?
|
| Prevalence | 2 | 2020 | 1609 | 0.130 |
Why?
|
| Placebos | 3 | 2010 | 195 | 0.130 |
Why?
|
| Abdominal Pain | 1 | 2015 | 97 | 0.130 |
Why?
|
| Cross-Sectional Studies | 1 | 2021 | 2264 | 0.130 |
Why?
|
| Lymphocytes | 1 | 2015 | 228 | 0.130 |
Why?
|
| Neutrophils | 1 | 2015 | 204 | 0.120 |
Why?
|
| Surveys and Questionnaires | 4 | 2016 | 2798 | 0.120 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2015 | 170 | 0.120 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2015 | 185 | 0.120 |
Why?
|
| Aspirin | 3 | 2009 | 295 | 0.120 |
Why?
|
| Bayes Theorem | 1 | 2015 | 303 | 0.120 |
Why?
|
| Referral and Consultation | 1 | 2015 | 383 | 0.110 |
Why?
|
| Registries | 2 | 2015 | 730 | 0.110 |
Why?
|
| Uncertainty | 1 | 2013 | 31 | 0.110 |
Why?
|
| Mental Recall | 1 | 2013 | 72 | 0.110 |
Why?
|
| Spirituality | 1 | 2013 | 38 | 0.110 |
Why?
|
| Cohort Studies | 2 | 2019 | 2356 | 0.110 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2014 | 373 | 0.110 |
Why?
|
| Immunohistochemistry | 2 | 2019 | 1174 | 0.100 |
Why?
|
| Double-Blind Method | 3 | 2010 | 1737 | 0.100 |
Why?
|
| Neoplasm Metastasis | 1 | 2013 | 306 | 0.100 |
Why?
|
| Predictive Value of Tests | 1 | 2015 | 1465 | 0.100 |
Why?
|
| Qualitative Research | 1 | 2013 | 368 | 0.100 |
Why?
|
| Activities of Daily Living | 1 | 2013 | 319 | 0.100 |
Why?
|
| Incidence | 2 | 2013 | 1582 | 0.100 |
Why?
|
| Young Adult | 3 | 2016 | 5708 | 0.100 |
Why?
|
| Estrogen Receptor alpha | 1 | 2010 | 65 | 0.090 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2010 | 146 | 0.090 |
Why?
|
| Social Support | 1 | 2013 | 423 | 0.090 |
Why?
|
| Intestinal Mucosa | 1 | 2010 | 219 | 0.090 |
Why?
|
| Medical History Taking | 2 | 2020 | 94 | 0.090 |
Why?
|
| Long Interspersed Nucleotide Elements | 1 | 2009 | 4 | 0.090 |
Why?
|
| Nails | 1 | 2009 | 15 | 0.090 |
Why?
|
| Precancerous Conditions | 1 | 2009 | 74 | 0.090 |
Why?
|
| Multicenter Studies as Topic | 1 | 2009 | 186 | 0.080 |
Why?
|
| Nicotine | 2 | 2022 | 350 | 0.080 |
Why?
|
| Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2008 | 12 | 0.080 |
Why?
|
| Nutrition Surveys | 2 | 2020 | 204 | 0.080 |
Why?
|
| Adolescent | 4 | 2016 | 8903 | 0.080 |
Why?
|
| Neoplasms | 1 | 2019 | 1660 | 0.080 |
Why?
|
| Genotype | 3 | 2022 | 785 | 0.080 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2009 | 239 | 0.080 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2009 | 231 | 0.070 |
Why?
|
| Antioxidants | 1 | 2009 | 304 | 0.070 |
Why?
|
| Calcium, Dietary | 1 | 2007 | 35 | 0.070 |
Why?
|
| Membrane Proteins | 1 | 2010 | 617 | 0.070 |
Why?
|
| Multivariate Analysis | 2 | 2019 | 1046 | 0.070 |
Why?
|
| Alcohol Drinking | 2 | 2009 | 805 | 0.070 |
Why?
|
| Genes, ras | 1 | 2006 | 46 | 0.070 |
Why?
|
| Chemoprevention | 1 | 2005 | 26 | 0.070 |
Why?
|
| Computer Simulation | 2 | 2019 | 705 | 0.070 |
Why?
|
| Antacids | 1 | 2005 | 26 | 0.070 |
Why?
|
| Calcium | 1 | 2009 | 929 | 0.070 |
Why?
|
| Selenium Compounds | 1 | 2004 | 14 | 0.060 |
Why?
|
| Prostatic Neoplasms | 2 | 2015 | 778 | 0.060 |
Why?
|
| Risk Assessment | 3 | 2007 | 2004 | 0.060 |
Why?
|
| Smell | 2 | 1995 | 131 | 0.060 |
Why?
|
| Obesity | 2 | 2016 | 1074 | 0.060 |
Why?
|
| Lung Neoplasms | 1 | 2013 | 1172 | 0.060 |
Why?
|
| Prospective Studies | 3 | 2020 | 3702 | 0.060 |
Why?
|
| Phenotype | 2 | 2021 | 946 | 0.060 |
Why?
|
| Cytochrome P-450 CYP2A6 | 1 | 2022 | 5 | 0.050 |
Why?
|
| Bupropion | 1 | 2022 | 63 | 0.050 |
Why?
|
| Genetic Variation | 1 | 2022 | 220 | 0.050 |
Why?
|
| Genes, MHC Class I | 1 | 2021 | 14 | 0.050 |
Why?
|
| Genes, MHC Class II | 1 | 2021 | 29 | 0.050 |
Why?
|
| Immunophenotyping | 1 | 2021 | 110 | 0.050 |
Why?
|
| Immunity, Cellular | 1 | 2021 | 80 | 0.050 |
Why?
|
| Exercise | 1 | 2005 | 657 | 0.040 |
Why?
|
| Datasets as Topic | 1 | 2019 | 52 | 0.040 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2022 | 627 | 0.040 |
Why?
|
| B-Lymphocytes | 1 | 2021 | 329 | 0.040 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2021 | 265 | 0.040 |
Why?
|
| Logistic Models | 2 | 2017 | 1419 | 0.040 |
Why?
|
| Gene Expression | 1 | 2021 | 770 | 0.040 |
Why?
|
| Macrophages | 1 | 2021 | 647 | 0.040 |
Why?
|
| Immunotherapy | 1 | 2019 | 212 | 0.040 |
Why?
|
| Software | 1 | 2019 | 418 | 0.040 |
Why?
|
| Combined Modality Therapy | 1 | 2018 | 951 | 0.030 |
Why?
|
| Lymphocyte Count | 1 | 2015 | 53 | 0.030 |
Why?
|
| Louisiana | 1 | 2015 | 37 | 0.030 |
Why?
|
| Odorants | 1 | 1995 | 52 | 0.030 |
Why?
|
| Monte Carlo Method | 1 | 2015 | 124 | 0.030 |
Why?
|
| Markov Chains | 1 | 2015 | 133 | 0.030 |
Why?
|
| Interviews as Topic | 1 | 2016 | 392 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2015 | 349 | 0.030 |
Why?
|
| Platelet Count | 1 | 2014 | 100 | 0.030 |
Why?
|
| Community-Based Participatory Research | 1 | 2016 | 133 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2014 | 110 | 0.030 |
Why?
|
| Comorbidity | 1 | 2018 | 1425 | 0.030 |
Why?
|
| Time Factors | 2 | 2015 | 4655 | 0.030 |
Why?
|
| Poisson Distribution | 1 | 2013 | 84 | 0.030 |
Why?
|
| Population Surveillance | 1 | 2014 | 285 | 0.030 |
Why?
|
| Telephone | 1 | 2013 | 160 | 0.030 |
Why?
|
| Vitamin B 6 | 1 | 2009 | 4 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2013 | 1341 | 0.020 |
Why?
|
| Alleles | 1 | 2008 | 386 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2008 | 546 | 0.020 |
Why?
|
| Polymorphism, Genetic | 1 | 2008 | 301 | 0.020 |
Why?
|
| Mice | 1 | 2019 | 8472 | 0.020 |
Why?
|
| Hyperthermia, Induced | 1 | 1987 | 53 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2006 | 159 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 1987 | 852 | 0.020 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2006 | 381 | 0.020 |
Why?
|
| Dietary Fiber | 1 | 2004 | 37 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2006 | 492 | 0.020 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2006 | 235 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2004 | 242 | 0.020 |
Why?
|
| Research Design | 1 | 2007 | 729 | 0.010 |
Why?
|
| Animals | 1 | 2019 | 20877 | 0.010 |
Why?
|
| Vitamin D | 1 | 2005 | 516 | 0.010 |
Why?
|
| Child, Preschool | 2 | 1995 | 3185 | 0.010 |
Why?
|
| Sensation Disorders | 1 | 1995 | 14 | 0.010 |
Why?
|
| Methods | 1 | 1995 | 156 | 0.010 |
Why?
|
| Photic Stimulation | 1 | 1995 | 229 | 0.010 |
Why?
|
| Reference Values | 1 | 1995 | 579 | 0.010 |
Why?
|
| Child | 2 | 1995 | 6400 | 0.010 |
Why?
|
| Aging | 1 | 1995 | 911 | 0.010 |
Why?
|
| Nigericin | 1 | 1987 | 3 | 0.000 |
Why?
|
| Calcimycin | 1 | 1987 | 32 | 0.000 |
Why?
|
| Ionophores | 1 | 1987 | 25 | 0.000 |
Why?
|
| Ouabain | 1 | 1987 | 32 | 0.000 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 1987 | 236 | 0.000 |
Why?
|
| Cell Line | 1 | 1987 | 1752 | 0.000 |
Why?
|